New methodology for pancreatic scintiscanning imaging using 125I-L-3 iodo-alpha-methyl tyrosine
Acta physiol. pharmacol. ther. latinoam
;
46(2): 83-9, 1996. tab, graf
Article
in English
| LILACS
| ID: lil-172312
RESUMO
The difficulty of a reliable diagnosis of pancreatic diseases by scintiscanning, is mainly derived from the lack of adequate radiopharmaceuticals. With this purpose (125) I-L(-3) Iodo-a-Methyl Tyrosine ((125) I-IMT) has been studied, which has also been used for the diagnosis of different kind of brain tumors. The purpose of this work is the development of a quick and easy method for the synthesis and purification of the (125) I-IMT in order to be used in a Nuclear Medicine Service. The L-(-Methly Tyrosine was labeled with (125) I using I-/I03 and afterwards purified by an aniomic exchange resin. The labeling yield obtained was (96.0+0.5) per cent when the incubation time was 15 minutes. No significant statistical differences were observed when the incubation time was extended to 1 hour. Biodistribution studies in mice show that the percentage of activity concentration in pancreas is (34.24+14.03) per cent at 15 minutes post injection, remaining constant for 30 minutes. The pancreas/liver ratio 15 minutes after the injection of the labeled product was (12.22+3.59) and it remained constant for 45 minutes more. These results show that (125) I-IMT cab be used as a diagnostic agent for pancreatic diseases. Since (123) I was not avilable at the moment, this new methodology was developed with (125) I.
Search on Google
Index:
LILACS (Americas)
Main subject:
Pancreatic Neoplasms
/
Diagnostic Imaging
/
Methyltyrosines
Type of study:
Diagnostic study
Limits:
Animals
Language:
English
Journal:
Acta physiol. pharmacol. ther. latinoam
Journal subject:
Pharmacology
/
Physiology
/
Therapeutics
Year:
1996
Type:
Article
/
Project document
Similar
MEDLINE
...
LILACS
LIS